The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Legembre, P.
Right arrow Articles by Taupin, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Legembre, P.
Right arrow Articles by Taupin, J.-L.
The Journal of Immunology, 2003, 171: 5659-5662.
Copyright © 2003 by The American Association of Immunologists


CUTTING EDGE

Cutting Edge: SDS-Stable Fas Microaggregates: An Early Event of Fas Activation Occurring with Agonistic Anti-Fas Antibody but Not with Fas Ligand 1

Patrick Legembre, Marie Beneteau, Sophie Daburon, Jean-François Moreau and Jean-Luc Taupin2

Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5540, Université de Bordeaux II, Bordeaux, France

The 45 kDa Fas or CD95 receptor triggers apoptosis via the caspase cascade when stimulated by its ligand FasL or by agonistic Abs. Activated Fas receptors seem to oligomerize very early into SDS-stable and reducing agent-resistant microaggregates of 200–250 kDa on SDS-PAGE. However, these microaggregates have so far only been reported using agonistic anti-Fas Abs, and no results have been reported using FasL. Here, we demonstrate that the microaggregates do not form in response to FasL, while they always appear in response to the agonistic Ab, in four different cell lines and in normal lymphocytes from human blood. Therefore, the Fas microaggregates are not required for the induction of apoptosis via FasL. These results also suggest that subtle differences exist in the apoptotic pathways triggered by anti-Fas agonistic Abs and by FasL.




This article has been cited by other articles:


Home page
J. Immunol.Home page
A.-L. Fauchais, F. Lalloue, M.-C. Lise, A. Boumediene, J.-L. Preud'homme, E. Vidal, and M.-O. Jauberteau
Role of Endogenous Brain-Derived Neurotrophic Factor and Sortilin in B Cell Survival
J. Immunol., September 1, 2008; 181(5): 3027 - 3038.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Beneteau, S. Daburon, J.-F. Moreau, J.-L. Taupin, and P. Legembre
Dominant-Negative Fas Mutation Is Reversed by Down-expression of c-FLIP
Cancer Res., January 1, 2007; 67(1): 108 - 115.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
F. Henkler, E. Behrle, K. M. Dennehy, A. Wicovsky, N. Peters, C. Warnke, K. Pfizenmaier, and H. Wajant
The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability
J. Cell Biol., March 28, 2005; 168(7): 1087 - 1098.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Giroux and F. Denis
CD1d-unrestricted human NKT cells release chemokines upon Fas engagement
Blood, January 15, 2005; 105(2): 703 - 710.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.